220 related articles for article (PubMed ID: 27784746)
1. CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.
Tian X; Nguyen M; Foote HP; Caster JM; Roche KC; Peters CG; Wu P; Jayaraman L; Garmey EG; Tepper JE; Eliasof S; Wang AZ
Cancer Res; 2017 Jan; 77(1):112-122. PubMed ID: 27784746
[TBL] [Abstract][Full Text] [Related]
2. Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
Lin CJ; Lin YL; Luh F; Yen Y; Chen RM
Oncotarget; 2016 Jul; 7(27):42408-42421. PubMed ID: 27285755
[TBL] [Abstract][Full Text] [Related]
3. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS
Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647
[TBL] [Abstract][Full Text] [Related]
5. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.
Pham E; Birrer MJ; Eliasof S; Garmey EG; Lazarus D; Lee CR; Man S; Matulonis UA; Peters CG; Xu P; Krasner C; Kerbel RS
Clin Cancer Res; 2015 Feb; 21(4):808-18. PubMed ID: 25524310
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.
Sanoff HK; Moon DH; Moore DT; Boles J; Bui C; Blackstock W; O'Neil BH; Subramaniam S; McRee AJ; Carlson C; Lee MS; Tepper JE; Wang AZ
Nanomedicine; 2019 Jun; 18():189-195. PubMed ID: 30858085
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.
Gaur S; Wang Y; Kretzner L; Chen L; Yen T; Wu X; Yuan YC; Davis M; Yen Y
Nanomedicine; 2014 Oct; 10(7):1477-86. PubMed ID: 24768630
[TBL] [Abstract][Full Text] [Related]
8. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.
Eliasof S; Lazarus D; Peters CG; Case RI; Cole RO; Hwang J; Schluep T; Chao J; Lin J; Yen Y; Han H; Wiley DT; Zuckerman JE; Davis ME
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):15127-32. PubMed ID: 23980155
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
Keefe SM; Hoffman-Censits J; Cohen RB; Mamtani R; Heitjan D; Eliasof S; Nixon A; Turnbull B; Garmey EG; Gunnarsson O; Waliki M; Ciconte J; Jayaraman L; Senderowicz A; Tellez AB; Hennessy M; Piscitelli A; Vaughn D; Smith A; Haas NB
Ann Oncol; 2016 Aug; 27(8):1579-85. PubMed ID: 27457310
[TBL] [Abstract][Full Text] [Related]
10. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.
Gaur S; Chen L; Yen T; Wang Y; Zhou B; Davis M; Yen Y
Nanomedicine; 2012 Jul; 8(5):721-30. PubMed ID: 22033079
[TBL] [Abstract][Full Text] [Related]
11. Correction: CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1
Cancer Res; 2017 Dec; 77(23):6790-6791. PubMed ID: 29196418
[No Abstract] [Full Text] [Related]
12. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
Voss MH; Hussain A; Vogelzang N; Lee JL; Keam B; Rha SY; Vaishampayan U; Harris WB; Richey S; Randall JM; Shaffer D; Cohn A; Crowell T; Li J; Senderowicz A; Stone E; Figlin R; Motzer RJ; Haas NB; Hutson T
Ann Oncol; 2017 Nov; 28(11):2754-2760. PubMed ID: 28950297
[TBL] [Abstract][Full Text] [Related]
13. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
[TBL] [Abstract][Full Text] [Related]
14. Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101.
Ng TS; Wert D; Sohi H; Procissi D; Colcher D; Raubitschek AA; Jacobs RE
Clin Cancer Res; 2013 May; 19(9):2518-27. PubMed ID: 23532891
[TBL] [Abstract][Full Text] [Related]
15. Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer.
Fernandes JM; Jandrey EHF; Koyama FC; Leite KRM; Camargo AA; Costa ÉT; Perez RO; Asprino PF
Dis Colon Rectum; 2020 Jul; 63(7):918-926. PubMed ID: 32229782
[TBL] [Abstract][Full Text] [Related]
16. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
Cancer; 2020 Jul; 126(14):3360-3371. PubMed ID: 32383803
[TBL] [Abstract][Full Text] [Related]
17. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.
Clark AJ; Wiley DT; Zuckerman JE; Webster P; Chao J; Lin J; Yen Y; Davis ME
Proc Natl Acad Sci U S A; 2016 Apr; 113(14):3850-4. PubMed ID: 27001839
[TBL] [Abstract][Full Text] [Related]
18. The combination of olaparib and camptothecin for effective radiosensitization.
Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
20. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Krasner CN; Campos SM; Young CL; Chadda KR; Lee H; Birrer MJ; Horowitz NS; Konstantinopoulos PA; D'Ascanio AM; Matulonis UA; Penson RT
Gynecol Oncol; 2021 Sep; 162(3):661-666. PubMed ID: 34243976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
